https://twitter.com/user/status/1788923517968265346 Our next @RenegadeRes Research roundtable is Thursday May 23rd. The topic is "T-cell dysfunction in #MECFS and #LongCovid " with researchers Liisa K. Selin, MD PhD; Anna Gil, PhD, viral immunologists from the University of Massachusetts Chan Medical School Roshan Kumar, PhD,… Show more https://www.remissionbiome.org/events/calendar
Can’t remember which but I think renegade research is “run by” remission biome, or the other way around.
Yeah I’m not saying I endorse them. Just that that might explain why this renegade research seminar includes remission biome.
As far as i know that drug is supposed to decrease inflammation through the microbiome. On ME-pedia it says atleast 2 different clinical trials have been started but none published, I wonder if they will be published in future or it was found to be ineffective. Given there are no published findings on it, them promoting the drug seems dodgy to me.
One of Oliver Sacks' encephalitis lethargica patients in Awakenings (Leonard L. ?), who responded dramatically to L-Dopa, called it something like Resurrectine. However, like all the patients who tried the drug, he soon regressed and eventually stopped taking it. You'd think that was a warning from recent history about inappropriate naming of drugs.